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Spontaneous mammary carcinoma in C3H mice is pre-
ceded by premalignant hyperplastic alveolar nodules. 
When a primary tumor is evident, examination of the 
other mammae will reveal a number of microscopic 
precancerous lesions in various stages of transformation 
to overt malignant tumors. In an effort to inhibit the 
development of addidonal malignant tumors after sur-
gical removal of the first apparent tumor, we treated 
female C3H/HeJ mice with subcutaneous injections of 
levamisole (0.6 mg per kg of body weight) on a twice 
weekly regimen. All further tumors were surgically 
excised when they became palpable. The surgical exci-
sion of bulk tumor burden, immunorestoration by 
levamisole, and the presence in the tumor cells of 
immunogenic surface antigens related to the virus all 
might be expected to enhance immunodulation of 
tumor cell growth or immunorejection of tumor cells. 
Immune activity measured by assaying macrophage 
migradon inhibition factor, extractable from spleno-
cytes, was significantly greater in the levamisole-treated 
mice than in the controls throughout the experiment. 
Although fewer tumors developed in the treated ani-
mals during the first eight weeks, this apparent effect of 
immunopertubation was only transitory. By the end of 
14 weeks, there was no longer a statistically significant 
difference in cumulative tumor index between the two 
groups. 
Evidence has accumulated that cancer patients have 
diminished immune defenses when compared to nor-
mal individuals (1). It has also been shown that a relation-
ship exists between the general immune status of the 
host and the clinical course of cancer (2). Concomitant 
with immunodepression in the cancer patient, a possible 
tumor cell immunoreject ion mechanism might also be 
impaired (1), so that normalization o f t he immune func-
t ion could become an important adjunct in cancer 
treatment. 
Levamisole, an antihelminthic drug, has been shown to 
potentiate immune responses in animals and humans 
(3-5). Indeed, Tr ipodi , et al (5) reported immunorestora-
t ion in anergic cancer patients after levamisole was 
administered. 
The development of spontaneous mammary tumors in 
mice is inf luenced by several factors, including the 
murine mammary tumor virus (MuMTV), specific genetic 
consti tut ion, and defined hormonal stimulus (6). Mam-
mary tumors and hyperplastic alveolar nodules (HANs), 
which are the morphological precursor of most mam-
mary tumors, develop with high frequency in C3H mice 
with vertically transmitted MuMTV (7). Although virgin 
and multiparous micewi l l haveessentiallythe same final 
tumor incidence, in parous females malignancy gener-
ally appears earlier. 
The development of humoral and cellular immunity 
directed against MuMTV in high mammary tumorstrains 
of mice is wel l known. Recently, Tagliabue, et al (8) 
demonstrated that cellular immune activity against 
MuMTV was not detectable by an indirect macrophage 
migration inhibit ion factor (MIF) procedure in C3H/HeN 
mice unti l they were approximately 14 weeks of age. 
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after which it became detectable before visible primary 
tumors developed. In this test system, immune activity 
tended to disappear by 36 weeks of age, when these 
mice were presumed to have subclinical tumors. A pos-
sible explanation for this immunodepression was pro-
vided by Creemers and Bentvelzen (9), who demon-
strated that cells that suppress lymphocyte proliferation 
appear during mammary tumor growth and reach peak 
activity when tumors attain a weight of 0.5 to 1.5 gm. 
To evaluate the efficacy of levamisole-induced immuno-
restoration in tumor cell growth inhibi t ion and/or 
tumor cell reject ion, we felt that the C3H/HeJ mouse 
would be a good model. Once the primary tumor 
becomes evident, the mouse should not be in an immu-
noactive state as it relates to the MuMTV cell surface 
antigens. By radically excising the macrotumor but leav-
ing relatively small numbers of active tumor cells in 
other primary microtumors, it should be possible to 
create a favorable situation in which the residual tumor 
cells would be susceptible to heightened immune activ-
ity. Therefore, if levamisole were effective in restoring 
immune cognizance of the tumor cell surface antigens, 
this renewed activity would be sufficient to suppress or 
reject the minimal tumor cell burden or inhibit the 
HANs from being transformed into overtly malignant 
tumors. 
Materials and Methods 
Animals 
We used female C3H/HeJ mice bred and raised in our 
own colony. All mice were mated, and after the first litter 
was weaned, they were placed in stock pens unti l a 
palpable mammary tumor developed. When primary 
tumors became grossly evident, the mice were random-
ized into one of four groups and treated as follows: 
1) 1° tumor: Mice were killed by cervical dislocation 
and the spleens removed. The splenocytes were pro-
cessed for the MIF assay to establish a baseline of MIF 
activity in the mice which developed tumors. 
2) Postsurgery: The tumors were surgically excised, the 
animals kept for one week, and then the spleens were 
removed for MIF assay to determine the level of activity 
in the absence of the major tumor burden. 
3) Surgical contro l : The primary, and all subsequent 
tumors arising in 90 days, were excised. The few mice 
that died during surgery had their spleens removed for 
MIF. The rest of the animals, 90 days after initial surgery, 
were kil led by cervical dislocation and the spleens 
removed for MIF. 
4) Levamisole-treated: Primary and subsequent tumors 
were resected as for the previous group. In addit ion, 
these mice were given twice weekly subcutaneous injec-
tions of levamisole that began two days after initial 
surgery and cont inued for 90 days. As before, at the t ime 
of accidental operative death or after 90 days, spleens 
were removed and used for MIF assay. 
5) Pretumor: An additional 22 mice, with no gross evi-
dence of tumor, were used at five months ofage to assay 
for MIF in pretumorous animals. 
Levamisole 
Levamisole phosphate (Ripercoll L, n;,ide by American 
Cyanamid Co), in an 18.2% injectable solution (equival-
ent to 136.5 mg of levamisole hydrochloride per ml) was 
di luted to0.06 mg per ml in sterileO.9% sodium chloride 
solution. All mice in the treatment group (group 4) 
received subcutaneous injections twice weekly (0.6 mg 
per kg of body weight) that started two days after the first 
tumor was removed and cont inued throughout the 
study. 
The pharmacology of levamisole has been studied 
extensively and the importance of the dose admini-
stered has been stressed (10,11). In preliminary studies, 
wi th normal BALB/c mice, levamisole at a dosage of 0.6 
mg/kg stimulated in vivo product ion of MIF, and weekly 
assays showed that MIF at high levels was maintained for 
fourweeks. However,at higher dosages of the drug (1.1, 
2.2, and 3.3 mg/kg) , in vivo product ion of MIF was stimu-
lated early but was no longer apparent after two weeks. 
MIF assay 
Based on the demonstrations that the lymphokine MIF is 
produced in vivo during periods of immunologic response 
(12-14) and that it can be extracted f rom lymphoid cells 
( including splenocytes) during such periods (12,15-17), 
we carried out the fol lowing procedure to evaluate 
immune activity in the experimental animals. Peritoneal 
exudate cells (PEC) were induced in BALB/c mice by 
intraperitoneal injection of 3 ml of sterile mineral oil at 
three-four days before harvesting. Extracts of spleno-
cytes were prepared as previously described (16), and 
PEC migration in Sykes-Moore chambers was assayed 
according to the method of Bloom, et al (18). 
In brief, capillary tubes containing a 10% (V:V) suspen-
sion of PEC were centr i fuged at 250 X g for 5 min. The 
capillary tubes were cut at the interface of packed cells 
and medium, and two packed tubes were placed in a 
Sykes-Moore chamber. One ml of medium plus0.2 ml of 
splenocyte extract was added to each chamber, except 
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for those for control migration, which contained medium 
only. After 20-22 hr of incubation at 37°C in a humidi fed 
5% C 0 2 incubator, migration areas were traced with a 
microscope viewing screen and the surface areas were 
determined. An index of PEC migration (Ml) was calcu-
lated by the fol lowing formula: 
M l = Average migration of four replicates with 
splenocyte extract ^ Average migration of four 
replicates with medium only 
Values of < 0.80 were generally considered positive 
for MIF. 
Results 
Splenocytes for MIF determination were obtained from 
at least 20 individual mice in each group. Migrat ion 
indices are shown in Fig. 1. 
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Fig.1 
Comparison of migrat ion indices for the f ive groups of C3H /He | mice 
studied. O p e n circles indicate mice w i th no gross evidence of tumor ; 
closed circles denote mice wh ich had a palpable tumor at the t ime 
spleen cells were harvested for MIF assay. 
Minor differences between the pretumor group, the 
one-week postsurgical, and control groups were not 
statistically significant, by the two-sample t test. The dif-
ference between the primary tumor group and both the 
pre tumorand one-week postsurgery groups was of bor-
derline significance (p<0.02), while the differences between 
the levamisole-treated animals and all other groups was 
highly significant (p<0.001). 
TABLE I 
Comparison of Average Values for Age of M ice at First Primary Tumor, 
Numbers of Second Primaries, and Immuno-act iv i ty Index 
Contro l Treated P* 
Group Group Value 
Age (in weeks) at first tumor 30.94 31.70 N S ' * 
(±5.74) (±5.65) 
Number of weeks evaluated 10.10 10.61 NS 
(±3.15) (±4.45) 
Number of addit ional tumors 4.23 3.60 NS 
per mouse (±3.37) (±2.60) 
Number of addit ional tumors 0.46 0.37 NS 
per mouse per week (±0.40) (±0.28) NS 
Macrophage migrat ion 0.89 0.64 0.0001 
inh ib i t ion index (±0.17) (±0.24) 
* Two = sample t test 
** NS = not significant 
Tumor incidence 
The numerical values shown in Table I indicate that mice 
in control and treated groups were well matched in all 
respects, except for MIF values. 
Because some mice died during surgery and some were 
arbitrarily sacrificed at dif ferent times in order to moni-
tor their activity, cumulative tumor incidence (CTI: 
number of tumors/mouse weeks survived) was used to 
correct for the variance of numbers in the two groups. At 
weeks 7 and 8 (Fig. 2), the levamisole-treated animals 
had a significantly lower tumor incidence than did con-
trols (p<0.001). By week 9, treated animals were devel-
oping more additional tumors than were controls. They 
cont inued to do so until the study ended at 14 weeks; at 
this point, the difference in CTl was no longer statisti-
cally significant at the 0.05 level. 
Autopsy findings were essentially similar in levamisole-
treated and surgical control mice: two instances of lung 
metastases were noted, one in each group. 
Discussion 
After the first appearance of a spontaneous mammary 
tumor, treatment of C3H/HeJ mice by surgical tumor 
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Fig. 2 
Cumulat ive Tumor Index 
CTI = accumulated number of tumors 
accumulated number of mouse weeks at risk 
A: CTI calculated weekly over the 14-week observat ion pe r iod ; B: CTI 
calculated weekly th rough week 8; C: CTI beginning at end of week 8 
and cont inu ing through week 14. 
excision and twice weekly subcutaneous injections of 
levamisole had a marked effect upon immune activity, as 
measured by the in vivo MIF throughout the 90-day 
period of observation. This treatment did not signifi-
cantly diminish the final incidence of further tumor 
development as compared to mice treated by sequential 
surgical excision of tumors only. However, in the 
levamisole-treated mice, there was an apparent inhibi-
tory effect on tumor incidence for the first eight-week 
period after immunotherapy was started. By the ninth 
week, this group of mice exhibited a sudden increase in 
the number of additional tumors, while the tumor inci-
dence in the surgical control group began to decline. By 
the end of 14 weeks, CTI was essentially similar in the two 
groups. 
Fidler and Spit ler (19), using two different transplantable 
mouse tumors, have reported that levamisole injection 
before tumor transplantation enhanced the early appear-
ance of neoplasms but had no effect on the overall 
incidence or course of tumor growth when compared to 
controls. In a study of immune response effect of levami-
sole on young adult and aged mice, Bruley-Rosset, et al 
(20) found that this compound was immunorestorative 
in aged mice, prolonged their survival, and seemed to 
reduce the incidence of spontaneous tumors by the t ime 
they were 24 months o ld . Padarathsingh, et al (21) also 
demonstrated that a single injection of levamisole (0.5 
mg/kg of body weight) was sufficient to restore immu-
nocompetence in BALB/c mice after plasmocytoma and 
drug-induced immunodepression. Sampson and Lui (22) 
found that levamisole was a nonspecific stimulator of 
human lymphocyte funct ion; later, however, Sampson, 
et al (10,11) demonstrated that high-dose levamisole was 
immunosuppressive in rats, whi le low dose levamisole 
was immunopotent iat ing. They also showed that inhibi-
t ion of growth of 7, 12-dimethylbenz (a) anthracene-
induced breast tumors in Sprague-Dawley rats was dose 
related; a high dose of levamisole (8 mg/kg) did not 
inhibi t tumor growth, whi le a low dose (2 and 4 mg/kg) 
inhibited good tumor growth. 
In this study, whi le tumor growth inhibi t ion did not 
continue beyond the eighth week of treatment, MIF 
values obtained at weekly intervals were consistently 
positive in the levamisole-treated mice and negative in 
the surgical control group throughout the study. 
Other studies that yielded positive, negative, and/or 
contradictory results have been carried out in animal 
models by the administration of levamisole before chal-
lenge with a transplanted tumor burden, although Fidler 
and Spitler (19) point out that a better model might bean 
animal wi th a spontaneous tumor which then receives 
the drug therapeutically. The C3H/Hej mouse, with a 
high incidence of spontaneous mammary tumors in 
breeding females, is such a model. This selection might 
be crit icized because the C3H/Hej mouse is known to 
have a macrophage defect that results in hyposensitivity 
to almost every known biologic effect of bacterial endo-
toxin (23). In addit ion, these macrophages demonstrate 
poor tumoricidal activity in vitro (24,25) and respond 
poorly to the lymphokine, migration inhibit ion factor 
(26). However, it has been shown in this strain that in vivo 
infection with Mycobacter ium bovis BCC activates the 
macrophages (24); Vogel, et al (27) showed that BCC 
stimulation restores practically all biologic effects of 
endotoxin except for the product ion of antibody to bac-
terial lipopolysaccharide. 
Our results indicate that levamisole d id, indeed, have a 
general stimulatory effect on immune activity of the 
C3H/HeJ mouse. Transient tumor growth inhibi t ion was 
observed. It has been recognized for some t ime that 
administration of immunostimulatory agents to experi-
mental animals, or to human patients with malignant 
disease, produces many immunological changes in the 
host. Certainly, the effect of these agents on tumor 
growth inhibi t ion appears to depend on a balance of 
immune reactions that are as yet unknown. 
This study indicates a real need for further investigations 
to elucidate more specific factors involved in immune 
system perturbation before such agents can be expected 
to contr ibute significantly to a more effective therapy of 
human cancer patients. 
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